BIOMAT Database Logo BIOMAT Database Logo

Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II. 1991

Y Christen, and B Waeber, and J Nussberger, and M Porchet, and R M Borland, and R J Lee, and K Maggon, and L Shum, and P B Timmermans, and H R Brunner
Hypertension Division, University Hospital, Lausanne, Switzerland.

BACKGROUND The purpose of the present study was to assess the inhibitory effect of DuP 753, an orally active angiotensin II receptor antagonist, on the pressor action of exogenous angiotensin I and II in healthy male volunteers. RESULTS In the first study (single-dose study), eight volunteers were included in a 2-day protocol repeated four times at 1-week intervals. In each phase, a different dose of drug (2.5, 5, 10, 20, or 40 mg) or placebo was given. The peak systolic blood pressure response to a test-dose of angiotensin I was determined serially before and after oral administration of DuP 753 by continuously monitoring finger blood pressure using a photoplethysmographic method. DuP 753 reduced the systolic blood pressure response to angiotensin I in a dose-dependent fashion. Three, 6, and 13 hours after the 40-mg dose, blood pressure response decreased to 31 +/- 5%, 37 +/- 6%, and 45 +/- 3% of the control values (mean +/- SEM, n = 7), respectively. In the second study, 29 volunteers were treated for 8 days with either a placebo or DuP 753 (5, 10, 20, or 40 mg p.o. q.d.) and challenged on the first, fourth, and eighth days with bolus injections of angiotensin II. Again, the inhibitory effect on the systolic blood pressure response to angiotensin II was clearly dose dependent. Six hours after 40 mg DuP 753, the systolic blood pressure response to the test-dose of angiotensin II was reduced to 37 +/- 7%, 40 +/- 4%, and 38 +/- 6% of baseline values (mean +/- SEM, n = 6) on days 1, 4, and 8, respectively. With this latter dose, there was still a blocking effect detectable 24 hours after the drug. Similar to angiotensin converting enzyme and renin inhibitors, DuP 753 induced a dose-dependent increase in plasma renin that was more pronounced on the eighth than on the first day of drug administration. In these normal volunteers, no consistent clinically significant side effects were observed. There was no evidence for an agonist effect. CONCLUSIONS DuP 753 appears to be a well-tolerated, orally active, potent, and long-lasting antagonist of angiotensin II in men.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D008297 Male Males
D012084 Renin-Angiotensin System A BLOOD PRESSURE regulating system of interacting components that include RENIN; ANGIOTENSINOGEN; ANGIOTENSIN CONVERTING ENZYME; ANGIOTENSIN I; ANGIOTENSIN II; and angiotensinase. Renin, an enzyme produced in the kidney, acts on angiotensinogen, an alpha-2 globulin produced by the liver, forming ANGIOTENSIN I. Angiotensin-converting enzyme, contained in the lung, acts on angiotensin I in the plasma converting it to ANGIOTENSIN II, an extremely powerful vasoconstrictor. Angiotensin II causes contraction of the arteriolar and renal VASCULAR SMOOTH MUSCLE, leading to retention of salt and water in the KIDNEY and increased arterial blood pressure. In addition, angiotensin II stimulates the release of ALDOSTERONE from the ADRENAL CORTEX, which in turn also increases salt and water retention in the kidney. Angiotensin-converting enzyme also breaks down BRADYKININ, a powerful vasodilator and component of the KALLIKREIN-KININ SYSTEM. Renin-Angiotensin-Aldosterone System,Renin Angiotensin Aldosterone System,Renin Angiotensin System,System, Renin-Angiotensin,System, Renin-Angiotensin-Aldosterone
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000803 Angiotensin I A decapeptide that is cleaved from precursor angiotensinogen by RENIN. Angiotensin I has limited biological activity. It is converted to angiotensin II, a potent vasoconstrictor, after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME.

Related Publications

Y Christen, and B Waeber, and J Nussberger, and M Porchet, and R M Borland, and R J Lee, and K Maggon, and L Shum, and P B Timmermans, and H R Brunner
DuP 753 is a specific antagonist for the angiotensin receptor.
April 1991, Hypertension (Dallas, Tex. : 1979),
Y Christen, and B Waeber, and J Nussberger, and M Porchet, and R M Borland, and R J Lee, and K Maggon, and L Shum, and P B Timmermans, and H R Brunner
Renin release induced by losartan (DuP 753), an angiotensin II receptor antagonist.
January 1993, Clinical and experimental hypertension (New York, N.Y. : 1993),
Y Christen, and B Waeber, and J Nussberger, and M Porchet, and R M Borland, and R J Lee, and K Maggon, and L Shum, and P B Timmermans, and H R Brunner
Proximal nephron and renal effects of DuP 753, a nonpeptide angiotensin II receptor antagonist.
September 1990, Kidney international,
Y Christen, and B Waeber, and J Nussberger, and M Porchet, and R M Borland, and R J Lee, and K Maggon, and L Shum, and P B Timmermans, and H R Brunner
The discovery of DuP 753, a potent, orally active nonpeptide angiotensin II receptor antagonist.
March 1992, Medicinal research reviews,
Y Christen, and B Waeber, and J Nussberger, and M Porchet, and R M Borland, and R J Lee, and K Maggon, and L Shum, and P B Timmermans, and H R Brunner
Further studies on the selectivity of DuP 753, a nonpeptide angiotensin II receptor antagonist.
April 1991, European journal of pharmacology,
Y Christen, and B Waeber, and J Nussberger, and M Porchet, and R M Borland, and R J Lee, and K Maggon, and L Shum, and P B Timmermans, and H R Brunner
Effect of a nonpeptide angiotensin II receptor antagonist, DuP 753, on angiotensin-related water intake in rats.
July 1991, Brain research bulletin,
Y Christen, and B Waeber, and J Nussberger, and M Porchet, and R M Borland, and R J Lee, and K Maggon, and L Shum, and P B Timmermans, and H R Brunner
Synthesis and identification of a novel tetrazole metabolite of the angiotensin II receptor antagonist DuP 753.
January 1991, Drug metabolism and disposition: the biological fate of chemicals,
Y Christen, and B Waeber, and J Nussberger, and M Porchet, and R M Borland, and R J Lee, and K Maggon, and L Shum, and P B Timmermans, and H R Brunner
The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonism.
August 1992, The Journal of pharmacology and experimental therapeutics,
Y Christen, and B Waeber, and J Nussberger, and M Porchet, and R M Borland, and R J Lee, and K Maggon, and L Shum, and P B Timmermans, and H R Brunner
DuP 753, a nonpeptide angiotensin II-1 receptor antagonist, alters dopaminergic function in rat striatum.
February 1992, Naunyn-Schmiedeberg's archives of pharmacology,
Y Christen, and B Waeber, and J Nussberger, and M Porchet, and R M Borland, and R J Lee, and K Maggon, and L Shum, and P B Timmermans, and H R Brunner
Angiotensin II and monocrotaline-induced pulmonary hypertension: effect of losartan (DuP 753), a nonpeptide angiotensin type 1 receptor antagonist.
September 1992, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!